Market open
Exelixis/$EXEL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Exelixis
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Ticker
$EXEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,147
Website
Exelixis Metrics
BasicAdvanced
$11B
21.32
$1.76
0.53
-
Price and volume
Market cap
$11B
Beta
0.53
52-week high
$37.64
52-week low
$20.14
Average daily volume
2.7M
Financial strength
Current ratio
3.635
Quick ratio
3.447
Long term debt to equity
8.503
Total debt to equity
9.617
Management effectiveness
Return on assets (TTM)
14.64%
Return on equity (TTM)
23.13%
Valuation
Price to earnings (TTM)
21.324
Price to revenue (TTM)
5.019
Price to book
4.71
Price to tangible book (TTM)
4.85
Price to free cash flow (TTM)
17.174
Growth
Revenue change (TTM)
18.49%
Earnings per share change (TTM)
170.77%
3-year revenue growth (CAGR)
14.76%
3-year earnings per share growth (CAGR)
34.71%
What the Analysts think about Exelixis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Exelixis stock.
Exelixis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Exelixis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Exelixis News
AllArticlesVideos
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
Business Wire·7 days ago
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
Business Wire·2 weeks ago
Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Exelixis stock?
Exelixis (EXEL) has a market cap of $11B as of February 27, 2025.
What is the P/E ratio for Exelixis stock?
The price to earnings (P/E) ratio for Exelixis (EXEL) stock is 21.32 as of February 27, 2025.
Does Exelixis stock pay dividends?
No, Exelixis (EXEL) stock does not pay dividends to its shareholders as of February 27, 2025.
When is the next Exelixis dividend payment date?
Exelixis (EXEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Exelixis?
Exelixis (EXEL) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.